Traditional Chinese Medicines as Anticancer Agents for Non-Small Cell Lung Cancer with EGFR Mutations: A Review
Zhiying Wang,1,* Zhixian Zhong,2,* Wenxiao Yang,1 Yun Li,3 Ke Zhang,3 Yabin Gong,1 Lijing Jiao,1,4 Ling Xu1,4 1Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 20043...
Saved in:
Main Authors: | Wang Z, Zhong Z, Yang W, Li Y, Zhang K, Gong Y, Jiao L, Xu L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/traditional-chinese-medicines-as-anticancer-agents-for-non-small-cell--peer-reviewed-fulltext-article-DDDT |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report
by: Ayuka Dai-Shinozaki, et al.
Published: (2025-01-01) -
OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01) -
First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01) -
Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations
by: Le LT, et al.
Published: (2025-07-01) -
Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
by: Yi‐Tse Su, et al.
Published: (2025-07-01)